StockNews.AI
PRCT
StockNews.AI
175 days

PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results

1. Q4 revenue rose 57% YoY to $68.2M, fueling market optimism. 2. FDA clearance for HYDROS marks a pivotal technological advancement. 3. Full-year revenue increased 65% with significantly improved gross margins. 4. 2025 guidance forecasts 42% revenue growth and stronger operating margins.

Earnings
+8.58%Current Return
VS
+0.04%S&P 500
$62.7302/25 04:09 PM EDTEvent Start
$68.1102/26 10:43 PM EDTLatest Updated
18m saved
Insight
Article

FAQ

Why Bullish?

The robust revenue growth, margin improvement, and key FDA milestones signal strong fundamentals for PRCT. Similar past earnings releases in high-growth tech sectors have driven notable price rallies.

How important is it?

This earnings release, with impressive revenue jumps and regulatory wins, is likely to have a significant impact on PRCT’s price trajectory.

Why Long Term?

The strategic product advancements and clinical trial approvals are expected to shape sustained growth over several years, as seen in other surgical robotics firms.

Related Companies

ISRGSYK
February 25, 2025 16:02 ET  | Source: PROCEPT BioRobotics SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue of approximately $68.2 million for the fourth quarter of 2024, an increase of 57% compared to the prior year periodU.S. system revenue of $27.6 million for the fourth quarter of 2024, an increase of 67% compared to the prior year periodSold 60 new robotic systems in the U.S. in the fourth quarter of 2024 at a blended average selling price of approximately $460,000U.S. handpiece and consumables revenue of $29.3 million for the fourth quarter of 2024, an increase of 36% compared to the prior year periodTotal revenue of $224.5 million for full year 2024, an increase of 65% compared to 2023Issued 2025 total revenue guidance of approximately $320 million, which would represent an increase of 42% compared to actual full year 2024 revenue “In pursuit of our long-term vision to transform the global treatment of BPH and ultimately build a global urology company, 2024 was a productive year for PROCEPT in two key areas," said Reza Zadno, Chief Executive Officer. “First, in August, we received FDA 510(k) clearance of our next-generation platform – the HYDROS™ Robotic System. This was a pivotal moment for the Company as HYDROS represents the first significant technological advancement compared to the AquaBeam® system. Second, we received FDA-IDE approval to initiate WATER IV PCa, a pivotal randomized clinical study for prostate cancer. As we enter 2025, we believe there are several positive factors that will enable us to continue to pursue our long-term growth strategy while continuing a disciplined approach on our path to profitability.” Fourth Quarter 2024 Financial Results Total revenue for the fourth quarter of 2024 was $68.2 million, an increase of 57% compared to the prior year period. The increase was primarily driven by increased system and handpiece sales, higher system average selling prices, and increased international revenue. U.S. system revenue was $27.6 million, an increase of 67% compared to the prior year period. As of December 31, 2024, the install base of AquaBeam and Hydros Robotic Systems in the U.S. was 505 systems. U.S. handpiece and consumable revenue for the quarter was $29.3 million, an increase of 36% compared to the prior year period. Due to an acute saline shortage in the fourth quarter of 2024, particularly in November 2024, the Company estimates reduced saline supply to hospital accounts resulted in a delay or cancellation of between 10 to 20 percent of Aquablation procedures - which ultimately impacted handpiece order patterns. International revenue was $7.8 million for the quarter, an increase of approximately 137% compared to the prior year period. Gross margin for the fourth quarter 2024 was 64% compared to 49% in the prior year period. Gross margin improvement was primarily due to improved overhead absorption, increased revenues, and increased U.S. robotic system average selling prices. Operating expenses in the fourth quarter of 2024 were $63.4 million, compared with $50.8 million in the prior year period. The increase in operating expenses was primarily due to expenses to expand the commercial organization, increased variable compensation expense and increased general and administrative expenses. Interest expense in the fourth quarter of 2024 was $1.0 million. Interest and other income in the fourth quarter of 2024 was $1.8 million. Interest and other income in the quarter was offset by foreign exchange loss headwinds. Net loss was $18.9 million for the fourth quarter of 2024, compared to a loss of $27.5 million in the prior year period. Adjusted EBITDA was a loss of $10.3 million for the fourth quarter of 2024, compared to a loss of $23.3 million in the prior year period. Cash and cash equivalents as of December 31, 2024 totaled $333.7 million, while long-term borrowings totaled $52.0 million. Full Year 2024 Financial Results Revenue for the full year 2024 was $224.5 million, compared to $136.2 million for the full year 2023. The growth was primarily driven by increases in U.S. revenues attributable to system placements and increased handpieces sold. Gross margin for full year 2024 was 61%, compared to 52% for the full year 2023. Gross margin improvement was primarily due to improved overhead absorption, increased revenues, and increased U.S. robotic system average selling prices. Operating expenses were $233.7 million for the full year 2024, compared to $180.2 million for the full year 2023, an increase of 30%. The increase was driven by increased sales and marketing expenses primarily to expand the commercial organization, and increased research and development and general and administrative expenses. Net loss was $91.4 million for the full year 2024, compared to $105.9 million for the full year 2023. Adjusted EBITDA was a loss of $61.1 million for full year 2024, compared to a loss of $86.5 million for the full year 2023. First Quarter of 2025 Financial Guidance The Company projects total revenue for the first quarter of 2025 to be approximately $65.5 millionThe Company projects U.S. system revenue for the first quarter of 2025 to be approximately $18.7 millionThe Company projects U.S. handpieces sold for the first quarter of 2025 to be approximately 10,750The Company projects first quarter of 2025 gross margin to be approximately 64%The Company projects first quarter of 2025 total operating expense of approximately $71.0 million 2025 Financial Guidance The Company projects revenue for the full year 2025 to be approximately $320 million, which would represent 42% growth over the Company’s prior year revenueThe Company projects full year 2025 gross margin to be approximately 64.5%The Company projects full year 2025 total operating expense of approximately $300 millionThe Company projects full year 2025 Adjusted EBITDA loss to be approximately $35 million Adjusted EBITDA is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).” Webcast and Conference Call Information PROCEPT BioRobotics will host a conference call to discuss the fourth quarter 2024 financial results after the market close on Tuesday, February 25, 2025, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/q33jvv92   Dial-in registration for sell-side research analysts: https://register.vevent.com/register/BI96427501b8ee48bdb09e18cb484392b0     Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. An archived recording will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be available for replay for at least 90 days after the event. About PROCEPT BioRobotics CorporationPROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. Use of Non-GAAP Financial Measures (Unaudited)This press release references Adjusted EBITDA, a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company defines Adjusted EBITDA as net income (loss) before interest expense, taxes, depreciation and amortization and stock-based compensation expense. Non-GAAP financial measures are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to any other performance measures derived in accordance with GAAP. The Company believes that presenting Adjusted EBITDA provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies. Forward Looking StatementsThis release contains forward‐looking statements within the meaning of federal securities laws, including with respect to the Company’s projected financial performance for full year 2024,   statements regarding the potential utilities, values, benefits and advantages of Aquablation® therapy performed using PROCEPT BioRobotics’ products, including AquaBeam® Robotic System, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on the Company’s current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which the Company is not currently aware.   Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, clinical trial outcomes, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margin, profitability, operating expenses, installed base growth, commercial momentum and overall business strategy. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s annual report on Form 10-K filed with the SEC on February 28, 2023 and subsequent quarterly reports on Form 10-Q and, when available, the Company’s annual report on Form 10-K for the year ended December 31, 2024. PROCEPT BioRobotics does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press release. Important Safety InformationAll surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/ Investor Contact:Matt BacsoVP, Investor Relations and Business Operationsm.bacso@procept-biorobotics.com PROCEPT BioRobotics CorporationCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited, in thousands, except per share data)        Three Months Ended December 31, Twelve Months Ended December 31,   2024   2023   2024   2023 Revenue $68,236  $43,581  $224,498  $136,191 Cost of sales  24,564   22,326   87,399   65,142 Gross profit  43,672   21,255   137,099   71,049 Operating expenses:        Research and development  15,066   14,496   62,298   48,446 Selling, general and administrative  48,316   36,316   171,415   131,773 Total operating expenses  63,382   50,812   233,713   180,219 Loss from operations  (19,710)  (29,557)  (96,614)  (109,170)Interest expense  (969)  (1,125)  (4,184)  (3,995)Interest and other income, net  1,823   3,178   9,385   7,268 Net loss $(18,856) $(27,504) $(91,413) $(105,897)Net loss per share, basic and diluted $(0.35) $(0.54) $(1.75) $(2.24)Weighted-average common shares used to        Compute net loss per share attributable to        Common shareholders, basic and diluted  53,838   50,589   52,125   47,255  PROCEPT BioRobotics CorporationRECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA(Unaudited, in thousands)        Three Months Ended December 31, Twelve Months Ended December 31,   2024   2023   2024   2023 Net loss $(18,856) $(27,504) $(91,413) $(105,897)Depreciation and amortization expense  1,453   1,318   5,234   3,807 Stock-based compensation expense  9,085   4,981   31,840   19,134 Interest (income) and interest expense, net  (2,017)  (2,079)  (6,711)  (3,556)Adjusted EBITDA $(10,335) $(23,284) $(61,050) $(86,512) PROCEPT BioRobotics CorporationRECONCILIATION OF GAAP NET LOSS TO ADJUSTED 2025 EBITDA Guidance(Unaudited, in thousands)      2025 Net loss $(80,000)Depreciation and amortization expense  6,800 Stock-based compensation expense  51,200 Interest (income) expense and other (income) expense, net  (13,000)Adjusted EBITDA $(35,000) PROCEPT BioRobotics CorporationCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited, in thousands)     December 31, December 31,   2024   2023 Assets    Current assets:    Cash and cash equivalents $333,725  $257,222 Restricted cash, current  —   — Accounts receivable, net  83,496   48,376 Inventory  56,168   39,756 Prepaid expenses and other current assets  8,453   5,213 Total current assets  481,842   350,567 Restricted cash, non-current  3,038   3,038 Property and equipment, net  26,709   28,748 Operating lease right-of-use assets, net  18,941   20,241 Intangible assets, net  932   1,204 Other assets  2,555   919 Total assets $534,017  $404,717      Liabilities and Stockholders' Equity    Current liabilities:    Accounts payable $10,032  $13,499 Accrued compensation  21,537   16,885 Deferred revenue  9,565   5,656 Operating leases, current  1,910   1,683 Loan facility derivative liability  2,000   1,886 Other current liabilities  8,089   6,318 Total current liabilities  53,133   45,927 Long-term debt  51,472   51,339 Operating lease , non-current  26,868   26,182 Other non-current liabilities  324   517 Total liabilities  131,797   123,965      Stockholders’ equity:    Additional paid-in capital  948,091   735,240 Accumulated other comprehensive loss  114   84 Accumulated deficit  (545,985)  (454,572)Total stockholders’ equity  402,220   280,752 Total liabilities and stockholders’ equity $534,017  $404,717  PROCEPT BioRobotics CorporationREVENUE BY TYPE AND GEOGRAPHY(Unaudited, in thousands)  Three Months Ended Twelve Months Ended  December 31, December 31,  2024 2023 2024 2023U.S.        System sales and rentals $27,636 $16,561 $78,614 $53,626Handpieces and other consumables  29,325  21,633  110,542  64,051Service  3,428  2,075  11,316  6,620Total U.S. revenue  60,389  40,269  200,472  124,297Outside of U.S.        System sales and rentals  3,711  1,398  11,685  5,294Handpieces and other consumables  3,689  1,645  10,914  5,471Service  447  269  1,427  1,129Total outside of U.S. revenue  7,847  3,312  24,026  11,894   Total revenue $68,236 $43,581 $224,498 $136,191

Related News